3 results match your criteria: "Tata Memorial Hospital Centre[Affiliation]"
Risk factors for the development of triple-negative breast cancer versus non-triple-negative breast cancer: a case-control study.
Sci Rep
August 2023
Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
The risk factors for breast cancer have been defined in several studies but there is deficient data for specific subtypes. We report here the pathological characteristics of a breast cancer cohort and risk factors for patients with triple-negative disease. In this case-control study, a prospective breast cancer cohort was evaluated for demographic, reproductive, obesity-related and other risk factors using a validated questionnaire.
View Article and Find Full Text PDFConventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
Head Neck
February 2016
Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India.
Background: The purpose of this study was to report the results of a phase III, 3-arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC).
Methods: One hundred eighty-six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66-70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m(2) ) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years.
Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
Head Neck
May 2015
Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital Centre, Kharghar, Navi Mumbai, India; Epidemiology and Clinical Trials Unit, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Hospital Centre, Kharghar, Navi Mumbai, India.
Background: Treatment intensification by using chemoradiotherapy (CRT) or altered fractionation radiotherapy (RT) improves outcomes in locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
Methods: Two comprehensive meta-analyses with similar control arms (conventionally fractionated RT) were compared indirectly.
Results: The hazard ratio (HR) of death with 95% confidence interval (CI) for the overall comparison of altered fractionation RT with concomitant CRT was 1.